Introduction {#s1}
============

Squamous cell carcinoma (SCC) is a type of epithelial cancer that is known to originate in the stratified squamous epithelia of the body, such as the skin, cervix, oesophagus, or oral cavity. Spindle cell carcinoma (spSCC) is a morphologically distinct type of cancer that consists of spindle-shaped non-epithelial cells, yet can occur in the same bodily locations as SCC. The cell type of origin for spSCC is thought to be epithelial, but is still not definitively established. Histological analysis of spindle cell carcinomas identified a 'sarcomatoid' morphology, resembling the mesenchymal fibroblasts of malignant fibrosarcomas, which suggests a possible mesodermal origin. However, the spindle-shaped tumour cells of spSCC may instead derive from epithelial cells of the epidermis via an epithelial-to-mesenchymal transition (EMT) ([@bib5]; [@bib37]), a process observed to occur in some mouse models of RasG12D-driven skin carcinomas ([@bib26]). Decisive demonstration of the cell of origin of spSCC requires additional mouse models for spSCC that allow for tracing of cell lineages.

The molecular basis for spSCC formation remains a fundamental unsolved problem. Recent work has identified the YAP oncoprotein, originally discovered to drive cell proliferation in *Drosophila* ([@bib20]), and later to drive liver tumours in mice ([@bib7]; [@bib13]) and to be mechanically regulated ([@bib14]). In skin, YAP is a driver of epidermal cell proliferation in mouse embryos ([@bib39]) and SCC formation in embryonic mouse skin after transplantation into nude mice ([@bib34]). YAP knockouts also prevent Ras-driven skin SCC formation ([@bib12]; [@bib38]). YAP is furthermore known to exhibit recurrent amplifications in human SCC tumours ([@bib19]; [@bib21]) and to promote human SCC cell proliferation in culture ([@bib36]). During normal skin development and homeostasis, YAP acts redundantly with its paralog TAZ to maintain proliferation of basal layer stem/progenitor cells and to promote wound healing ([@bib16]). Integrin-SRC signalling promotes YAP activity in cell culture, mouse skin and in human SCC cells in culture ([@bib16]; [@bib22]; [@bib29]). Thus, formation of SCC may occur simply by an acceleration of the normal YAP-dependent program of basal layer cell proliferation to produce an overgrown epidermis. In contrast, the molecular basis of SCC progression to spSCC remains poorly understood.

Results and discussion {#s2}
======================

We sought to test whether YAP is involved in formation of spSCC as well as SCC. To address this question, we stained histological sections of normal human skin and human spSCC tumours with an anti-YAP antibody and an anti-Keratin-5 (K5) antibody to mark epidermal cells ([Figure 1A--C](#fig1){ref-type="fig"}). YAP is normally expressed primarily in the epidermis, and is nuclear localised in the basal layer stem progenitor cells ([Figure 1B,C](#fig1){ref-type="fig"}). In spSCC tumours, YAP is strongly expressed and nuclear localised throughout the tumour, despite the fact that the tumour is dermal rather than epidermal in character as revealed by the absence of K5 expression in the tumour ([Figure 1A--C](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We note that spSCC tumours are often associated with a wounded epidermis, as indicated by a gap in the K5-positive layer above the tumour. These results suggest that high levels of nuclear YAP and epidermal wounding may be involved in spSCC formation.

![YAP is nuclear localised in human spindle cell carcinoma.\
(**A**) Histological sections of normal human skin and spindle cell carcinoma patient tumour stained for the epithelial marker Keratin-5 (brown immunostain). Scale bar 200 μM. (**B**) Histological sections of normal human skin and spindle cell carcinoma patient tumour stained for YAP (brown immunostain). Scale bar 200 μM. (**C**) High magnification view of (**B**) showing nuclear localisation of YAP protein in spindle cell carcinoma (brown immunostain). Sections are co-stained for eosin (blue). Scale bar 200 μM.](elife-33304-fig1){#fig1}

To test this notion, we generated a conditionally inducible YAP transgene (Rosa26 LoxSTOPLox NLS-YAP-5SA IRES LacZ) that can be activated by expression of the Cre recombinase enzyme. We included a lineage tracer (LacZ) to identify all daughter cells deriving from mother cells undergoing Cre-mediated recombination. Crossing this transgene with a Keratin-5 driven, tamoxifen-inducible, Cre recombinase line (K5-CreERt) enabled conditional expression of oncogenic NLS-YAP-5SA in skin epidermis after treatment with tamoxifen to induce nuclear localisation of the CreERt enzyme and excision of the PolyA-containing STOP cassette ([Figure 2A](#fig2){ref-type="fig"}). We find that NLS-YAP-5SA is able to induce formation of both SCC and spSCC in skin within 2--4 weeks of tamoxifen treatment ([Figure 2B](#fig2){ref-type="fig"}). SCC and spSCC can be distinguished because spSCC tumour cells are dermally located and lack expression of K5 ([Figure 2B](#fig2){ref-type="fig"}). Notably, spSCC tumours tended to arise in regions where the mice scratch their skin, and spSCC tumours were often associated with a wounded epidermis, while SCCs could arise in the absence of epidermal wounding ([Figure 2B](#fig2){ref-type="fig"}). These findings raise the question of how expression of oncogenic YAP in the K5-positive epidermal cells can give rise to K5-negative dermal spSCC, and whether wounding of the skin has a role in the process.

![Nuclear YAP drives formation of both SCC and spSCC in mice.\
(**A**) Skin-specific expressison of nuclear YAP was achieved by crossing K5-CreERt mice to a Lox-Stop-Lox cassette for conditional expression of nuclear YAP and a LacZ lineage tracer in basal layer skin cells. (**B**) Expression of nuclear YAP drives formation of both SCC-like overgrowths (Keratin-5 positive) and spSCC-like tumours (mostly Keratin-5 negative). Multiple spSCC tumours arise per animal, but only in areas subject to scratch wounding. Note the disruption in the continuity of Keratin-5 positive epithelial layer above the spSCC tumour, indicative of a wound-induced tumour (*n* = 20). Kaplan-Meier analysis shows rapid induction of tumours in NLS-YAP-5SA expressing skin. (**C**) Lineage tracing with LacZ (encoding nuclear beta-Gal immunostained in brown) induced with the K5-CreERt line indicates that both SCC and spSCC tumours arise from the K5-positive basal layer of the skin (*n* = 22). (**D**) Proliferation of cells was measured by staining for the mitotic marker Ki-67 in control, SCC and spSCC samples (*n* = 25). Scale bars 100 μM. (**E**) Quantification of C and D in epidermal (**E**) vs dermal (**D**) compartments.](elife-33304-fig2){#fig2}

To follow the lineage of spSCC cells, we stained NLS-YAP-5SA expressing mouse skin for nuclear beta-Galactosidase (the product of the *LacZ* gene), which becomes expressed upon K5-CreERt-mediated recombination. Following treatment with tamoxifen for 5 days, nuclear beta-Gal expression was detected in patches of epidermal cells in skin areas not subject to scratch wounds ([Figure 2C](#fig2){ref-type="fig"}). In regions subject to scratching, large spSCCs formed with clear nuclear beta-Gal expression in all tumour cells and some neighbouring epidermal cells ([Figure 2C](#fig2){ref-type="fig"}). The spSCC tumours were highly proliferative, as indicated by Ki67-positive immunostaining ([Figure 2D,E](#fig2){ref-type="fig"}). These results demonstrate that oncogenic YAP drives spSCC formation by metaplastic transformation of K5-positive epidermal basal layer epithelial cells into K5-negative dermal mesenchymal spindle cells.

To explore the mechanism of metaplastic transformation during oncogenic YAP-driven spSCC formation, we examined the expression of classic epithelial-to-mesenchymal transition (EMT) markers ([@bib37]). A defining feature of EMT is the downregulation of epithelial markers such E-cadherin or Keratins and upregulation of Vimentin. In nuclear YAP-driven tumours, Keratin-5 expression is inactivated and Vimentin expression is strongly induced upon transformation of SCC to spSCC following wounding ([Figure 3A,B](#fig3){ref-type="fig"}). EMT is known to be driven by E-box DNA binding transcription factors such as Twist (mammalian TWIST1), Snail (mammalian SNAI1 and SNAI2/SLUG), and Zfh1/2 (mammalian ZEB1/2) -- all originally discovered in *Drosophila*, and then in other model organisms, to promote mesodermal rather than ectodermal fate during developmental EMT ([@bib3]; [@bib6]; [@bib17]; [@bib24], [@bib25]; [@bib28]; [@bib31], [@bib32]; [@bib35]). We chose to focus on ZEB1 because (1) in *Drosophila*, Zfh1/2 are expressed downstream of Twist and Snail ([@bib24]), (2) in mammalian cells in culture, ZEB1 (also called deltaEF1) and ZEB2 (also called SIP1) are known to be potent inducers of EMT ([@bib1]; [@bib9]; [@bib15]; [@bib23]) and (3) ZEB1 was recently shown to cooperate with YAP to drive a common set of target genes in cell culture ([@bib27]). In vivo, we find that ZEB1 mRNA and protein is normally not expressed in epithelial cells or SCC but becomes strongly expressed in oncogenic YAP-driven spSCC tumour cells, similar to SNAIL1 mRNA ([Figure 3C--F](#fig3){ref-type="fig"}). These results indicate that YAP-driven spSCC arises via an EMT program involving expression of ZEB1.

![YAP-driven mouse spSCC formation involves transcriptional induction of ZEB1 expression and EMT.\
(**A**) YAP immunostaining of control skin as well as NLS-YAP-5SA driven SCC and spSCC tumours (*n* = 32). (**B**) Vimentin (mesenchymal marker) immunostaining of control skin as well as NLS-YAP-5SA driven SCC and spSCC tumours. Note strong induction in spSCC (*n* = 30). (**C**) ZEB1 (EMT transcription factor) immunostaining of control skin as well as NLS-YAP-5SA driven SCC and spSCC tumours. Note strong induction in spSCC (*n* = 33). (**D**) *ZEB1* mRNA in situ hybridisation of control skin as well as NLS-YAP-5SA driven SCC and spSCC tumours. Note strong induction in spSCC (*n* = 29). (**E**) *SNAIL1* mRNA in situ hybridisation of control skin as well as NLS-YAP-5SA driven SCC and spSCC tumours. Note strong induction in spSCC (*n* = 8). (**F**) Quantitation of YAP and ZEB1 marker expression in samples from wild-type skin, SCC-like, and spSCC-like mouse skin tumours (n \> 30 samples for each case). Scale bars 50--100 μM.](elife-33304-fig3){#fig3}

Importantly, we find that ZEB1 is also induced during the wound healing response in normal skin epithelia and in cultured skin keratinocytes ([Figure 4A,B](#fig4){ref-type="fig"}). Since the wound-induced upregulation of YAP and ZEB1 can be recapitulated in cultured keratinocytes, we examined whether the induction of ZEB1 expression that occurs during wound healing requires active YAP. To inhibit YAP activation, we treated scratch-wounded keratinocyte monolayers with either siRNAs targeting YAP/TAZ or with the Src family kinase inhibitor Dasatinib, which is known to strongly inhibit YAP activation ([@bib16]; [@bib22]; [@bib29]). We find that inhibition of YAP activity with this compound prevents activation of ZEB1 expression at 4 hr after scratch wounding ([Figure 4C,D](#fig4){ref-type="fig"}). These observations indicate that wound-induced ZEB1 expression is normally sustained by YAP activity. To confirm that YAP acts via TEAD-dependent transcription, we silenced expression of TEAD1-4 with siRNAs, which prevented ZEB1 induction after scratch wounding ([Figure 4E](#fig4){ref-type="fig"}). Finally, we were able to detect TEAD1 binding to an upstream enhancer at the *ZEB1* locus upon scratch wounding, although the degree of enrichment is weak due to the very small percentage of *ZEB1* expressing cells in this experiment ([Figure 4F](#fig4){ref-type="fig"}). Importantly, the physiological upregulation of YAP and ZEB1 following wounding is only transient, as these genes are normally silenced following wound closure, which inhibits YAP. In contrast, ZEB1 expression is not silenced in the presence of oncogenic NLS-YAP-5SA, allowing ZEB1 to drive EMT and spSCC formation ([Figure 3A--C](#fig3){ref-type="fig"}). Finally, we sought to confirm that our findings with transgenic mice also apply to humans. We first confirmed that ZEB1 becomes co-expressed with YAP and that there is a loss of E-cadherin and gain of Vimentin expression in human spSCC tumours ([Figure 5A--D](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

![YAP promotes ZEB1 expression after epidermal wounding to drive EMT.\
(**A**) Punch wounding of mouse skin induces ZEB1 immunostaining in some leading edge cells. Scale bars 100 μM. (**B**) Scratch wounding of skin keratinocytes in culture induces ZEB1 and YAP immunostaining in leading edge cells. Scale bar 50 μM. (**C**) Induction of ZEB1 at the leading edge is prevented by transfection with siRNAs against YAP/TAZ. Scale bar 50 μM. (**D**) Induction of ZEB1 at the leading edge is prevented by treatment with Dasatinib, a Src-family kinase inhibitor that prevents YAP activation. Scale bar 50 μM. (**E**) Induction of ZEB1 at the leading edge is prevented by treatment with siRNAs against TEAD1-4. Scale bar 50 μM. (**F**) Chromatin Immunoprecipitation of TEAD1 at an upstream enhancer of the *ZEB1* gene in keratinocytes before or after scratch wounding. The weak enrichment may be caused by the small percentage of *ZEB1*-expressing cells in this experiment. Data were analysed by a Mann-Whitney Test n = 9 samples per experimental condition.](elife-33304-fig4){#fig4}

![Human spSCC is characterised by co-expression of YAP and ZEB1.\
(**A**) YAP immunostaining of normal human skin, SCC and spSCC-like tumours. Note strong nuclear localisation in spindle-shaped spSCC tumour cells. (**B**) ZEB1 immunostaining of normal human skin, SCC and spSCC-like tumours. Note strong expression in spindle-shaped spSCC tumour cells. (**C**) Vimentin immunostaining of normal human skin, SCC and spSCC-like tumours. Note strong expression in spindle-shaped spSCC tumour cells. (**D**) E-cadherin immunostaining of normal human skin, SCC and spSCC-like tumours. Note absence of expression in spindle-shaped spSCC tumour cells. (**E**) Model comparing normal wound healing with SCC and spSCC formation. Scale bars 100 μM.](elife-33304-fig5){#fig5}

In conclusion, our findings identify YAP as a driver of both SCC and spSCC formation, demonstrate that both SCC and spSCC originate in the basal layer of the epidermis, and reveal that the SCC versus spSCC outcome is determined by whether or not tumour cells undergo a ZEB1-mediated EMT program that can be induced by skin wounding ([Figure 5E](#fig5){ref-type="fig"}). Thus, while SCC reflects an abnormal hyperactivation of homeostatic epidermal proliferation mechanisms (requiring YAP/TAZ ([@bib12]) but not ZEB1, which is not expressed in SCC), spSCC reflects an abnormal hyperactivation of wound repair proliferation and EMT mechanisms (driven by both YAP and ZEB1). Future work should aim to examine genetic deletion of ZEB1 in spSCC tumours ([@bib4]) and precisely how the wounding event synergises with YAP to induce ZEB1 and EMT, as many other wound-induced signal transduction pathways (MRTF-SRF, Ras-AP1, TGFbeta-SMAD) have been implicated in EMT and have binding sites in the *ZEB1* regulatory region ([@bib2]; [@bib5]; [@bib10]; [@bib11]; [@bib18]; [@bib33]; [@bib37]). Overall, our findings begin to provide a molecular understanding of how genetic changes lead to SCC tumour growth and subsequent transformation to spSCC, and explain why exposure of skin to trauma, burns or ionizing radiation are so commonly associated with spSCC formation in patients ([@bib30]).

Materials and methods {#s3}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation          Source or reference             Identifiers                                                       Additional information
  or resource                                                                                                                                      
  ------------------------- -------------------- ------------------------------- ----------------------------------------------------------------- --------------------------------
  Cell Line (Human)         HaCAT                Cell Services\                  (CLS Cat\# 300493/p800_HaCaT,\                                    
                                                 (Francis Crick Institute)\      RRID:[CVCL_0038](https://scicrunch.org/resolver/CVCL_0038))       
                                                 Pubmed ID: 26989177                                                                               

  Antibody\                 anti-Vimentin        Abcam                           (Abcam Cat\# ab92547,\                                            1/600 IHC
  (Rabbit monoclonal)                                                            RRID:[AB_10562134](https://scicrunch.org/resolver/AB_10562134))   

  Antibody\                 anti-ZEB1            Proteintech                     (Proteintech Group\                                               1/500 IHC/1/100 IF
  (Rabbit polyclonal)                                                            Cat\# 21544--1-AP,\                                               
                                                                                 RRID:[AB_10734325](https://scicrunch.org/resolver/AB_10734325))   

  Antibody\                 anti-Keratin-5       Abcam                           (Abcam Cat\# ab52635,\                                            1/500 IHC
  (Rabbit monoclonal)                                                            RRID:[AB_869890](https://scicrunch.org/resolver/AB_869890))       

  Antibody\                 anti-beta-\          Acris                           (Acris Antibodies GmbH\                                           1/5000 IHC
  (Rabbit polyclonal)       galactosidase                                        Cat\# R1064P,\                                                    
                                                                                 RRID:[AB_973264](https://scicrunch.org/resolver/AB_973264))       

  Antibody\                 anti-E-Cadherin      Santa Cruz                      (Santa Cruz Biotechnology\                                        1/75 IHC
  (Rabbit polyclonal)                                                            Cat\# sc-7870,\                                                   
                                                                                 RRID:[AB_2076666](https://scicrunch.org/resolver/AB_2076666))     

  Antibody\                 anti-YAP             Cell Signalling\                (Cell Signaling Technology\                                       1/400 O/N IHC
  (Rabbit monoclonal)                            Technology                      Cat\# 14074,\                                                     
                                                                                 RRID:[AB_2650491](https://scicrunch.org/resolver/AB_2650491))     

  Antibody\                 anti-Ki67            Abcam                           (Abcam Cat\# ab16667,\                                            1/350 IHC
  (Rabbit monoclonal)                                                            RRID:[AB_302459](https://scicrunch.org/resolver/AB_302459))       

  Antibody\                 anti-TEAD-1          BD Biosciences                  (BD Biosciences Cat\# 610922,\                                    12.5 per 200 ug chromatin\
  (Mouse monoclonal)                                                             RRID:[AB_398237](https://scicrunch.org/resolver/AB_398237))       input CHIP

  Antibody\                 anti-YAP             Santa Cruz                      (Santa Cruz Biotechnology\                                        1/100 IF
  (Mouse monoclonal)                                                             Cat\# sc-101199,\                                                 
                                                                                 RRID:[AB_1131430](https://scicrunch.org/resolver/AB_1131430))     

  Transfection reagent      Lipofectamine\       Thermo Fisher                   Cat no: 13778075                                                  
                            RNAiMAX                                                                                                                

  siRNA                     TEAD 1               Dhamacon                        Cat no: M-012603-01-0005                                          80 nM Final

  siRNA                     TEAD 2               Dhamacon                        M-012611-00-0005                                                  80 nM Final

  siRNA                     TEAD 3               Dhamacon                        M-012604-01-0005                                                  80 nM Final

  siRNA                     TEAD 4               Dhamacon                        M-019570-03-0005                                                  80 nM Final

  siRNA                     YAP                  Dhamacon                        M-012200-00-0005                                                  80 nM Final

  Human Protein Atlas       Various              Pubmed ID: 16774037             <https://www.proteinatlas.org/>                                   

  Human cancer samples      Vimentin/YAP         University of Southamption/\                                                                      
                                                 Gareth Thomas                                                                                     

  Chemical compound,\       Dasatinib            Selleck Biochem                 S1021                                                             5 uM Final
  drug                                                                                                                                             

  Mouse strain              Rosa26-YAP5SA        Junhao Mao (University of\                                                                        mixed background
                                                 Massachusetts Medical School)                                                                     

  Mouse strain              K5-CreERT2           Ian Rosewell\                                                                                     mixed background
                                                 (Francis Crick Institute)                                                                         

  Mouse strain              Yapfl/fl Tazfl/fl    Axel Behrens\                                                                                     mixed background
                                                 (Francis Crick Institute)                                                                         

  Chemical compound,\       4-Hydroxytamoxifen   Sigma                           H7904                                                             topical application of 200 ul\
  drug                                                                                                                                             oF 1.0 mg per 0.1 mL 4'OHT\
                                                                                                                                                   in DMSO on dorsal skin 5x\
                                                                                                                                                   consecutive days

  Chemical compound,\       Tamoxifen            Sigma                           T5648                                                             IP 5 ul/g body weight of a 20\
  drug                                                                                                                                             mg/ml solution in corn oil 5x\
                                                                                                                                                   consecutive days

  RNA target probe          RNAscope Probe -\    ACD                             451201                                                            
                            Mm-Zeb1                                                                                                                

  RNA target probe          RNAscope Probe -\    ACD                             451211                                                            
                            Mm-Snai1                                                                                                               

  RNA target probe          RNAscope Probe -\    ACD                             **451191**                                                        
                            Mm-Snai2                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture {#s3-1}
------------

Human HaCAT cells (Francis Crick Institute cell services) were grown in DMEM (Gibco 41966) with 10% FCS and Penicillin/Streptomycin. All cells are subject to mycoplasma testing.

Cell culture scratch assay {#s3-2}
--------------------------

Cells are transfected with siRNA as previously described (Ref 13), before being replated at high density and left for 24 hr. Cells are scratched with a P200 pipette tip and left for 4 hr before being fixed. Cells treated with Dasatinib were treated and scratched simultaneously before being fixed. Cells were fixed with 4% PFA for 15 min before permeabilsing as previously described (Ref 13).

Cell culture antibodies, image acquisition and quantification {#s3-3}
-------------------------------------------------------------

Primary antibodies used were: Rabbit Zeb1 Proteintech 21544-AP) 1/100 and Mouse YAP (Santa cruz sc-101199) 1/100. Secondary antibodies were from Invitrogen, and used at 1:500 for 2 hr at room temperature along with DAPI. Cell culture samples were imaged with a Leica SP5 confocal microscope using a 63x oil immersion objective and processed using Adobe Photoshop. Cells were assessed over three independent experiments counting 200--300 cells per condition.

siRNA transfection and inhibitor treatments  {#s3-4}
--------------------------------------------

siRNA transfection experiments and inhibitor treatments were performed as previously described (Ref [@bib13]).

Plasmids pCMV6 AC GFP ZEB-1 Transcript 1 (Origene) was transfected using Lipofectamine 3000 (Invitrogen). Quantification of extruded cells was performed by analysing n342 transfected cells over three experiments and recording number of extruded cells versus cells present within the monolayer.

Chromatin immunoprecipitation {#s3-5}
-----------------------------

ChIP was performed as previously described ([@bib8]), with the exception of the use of the ChIP Clean and Concentrate kit (Zymo Research, USA) for clean up of enriched chromatin according to the manufacturer's instructions. Quantitative PCR for enrichment at the *ZEB1* promoter was performed using the following primers: Fwd: 5'-GATGGGGAAGTGAGACAAGC-3'; Rev: 5'-CAGCTGGATTGAAAGAGAGGC-3'.

Animal procedures {#s3-6}
-----------------

### Ethics statement {#s3-6-1}

All animal-regulated procedures were carried out according to Project License constraints (PPL 70/7926) and Home Office guidelines and regulations.

All experiments were carried out in accordance with the United Kingdom Animal Scientific Procedures Act (1986). 

### pROSA26-YAP5SA targeting construct {#s3-6-2}

Diagram of the construct is shown in [Figure 2](#fig2){ref-type="fig"}. K5-CreERt mice were in mixed background. ROSA26-YAP5SA-NLS K5-CreERt mice were used with littermate controls.

Mouse experiments {#s3-7}
-----------------

### R26-YAP5SA-NLS transgene expression in adult epidermis {#s3-7-1}

Tamoxifen (Sigma, 20 mg/ml in con oil) was injected intraperitoneally (IP) (5 µl/g body weight) for five consecutive days into 8--16 week old controls or transgenic animals carrying K5-CreERt Yap R26-YAP5SA-NLS to induce YAP5SA-NLS expression and analyzed for LacZ (lineage tracer) expression by immunohistochemistry from 3 days thereafter. K5-CreERt R26-YAP5SA-NLS mice used for tumour formation analysis were analyzed by immunohistochemistry from 10 days after the initial tamoxifen treatment start.

Wound healing {#s3-8}
-------------

Following the 5 day tamoxifen treatment, four hydroxy-tamoxifen (4OHT, sigma) was topically applied to shaved backskin for five consecutive days at a dosage of 10 mg/ml in Ethanol and 100 µl was applied per mouse. Mice were anaesthetized with IsoFlo (Isoflurane, Abbott Animal Health) and treated with the analgesics Vetergesic (Alstoe Animal Health) and Rimadyl (Pfizer Animal Health) for 2 days after wounding. A 4 mm punch wound was made in the backskin using a biopsy punch (Miltex) and mice were culled 48 hr later, with the wound section harvested and fixed immediately for immunohistochemical analysis.

Immunohistochemistry {#s3-9}
--------------------

Mouse backskin samples were harvested and fixed in neutral-buffered formaldehyde 10% vol/vol (sigma) and then embedded in paraffin in a head to tail orientation. The tissues were processed, embedded and sectioned at 4 [µ]{.ul}m and used for hematoxylin--eosin staining and immunohistochemistry. Sections were de-waxed in xylene, dehydrated by passage through graded alcohols to water. If required for antigen retrieval, sections were microwaved in citrate buffer pH6 for 15 min and then transferred to PBS. Endogenous peroxidase was blocked using 1.6% hydrogen peroxide in PBS for 10 min followed by washing in distilled water. Species specific blocking serum (Diluted to 10% in 1% BSA) was used to block non-specific staining in the tissue for 30 min. Slides were incubated with Primary antibody diluted to 1:100 in 1% BSA for 1 hr at room temperature. Sections were washed in PBS prior to applying the appropriate biotinylated secondary antibody for 45 min at room temperature. Sections were then washed in PBS and then incubated in ABC (Vector Laboratories PK-6100) for 30 min. Following washing in PBS, DAB solution was applied for 2--5 min with development of the colour reaction being monitored microscopically. Slides were washed in tap water, stained with a light haematoxylin, dehydrated, cleared and then mounted. Antibodies used for IHC were: Vimentin (Abcam ab92547) 1/600, Zeb1 (Proteintech 21544-AP) 1/500, Keratin-5 Abcam ab52635) 1/500, LacZ (Acris R1064P) 1/5000, E-Cadherin (Santa Cruz sc-7870) 1/75 O/N, YAP Cell signalling (14074) 1/400 O/N; (Santa cruz sc-101199) 1/200 O/N, Ki67 (Abcam ab16667) 1/350. Images were acquired with a Zeiss light microscope using 40x and 20x objectives. Additional images of human samples were obtained by data-mining the proteinatlas.org database.

RNAscope (ACDbio) {#s3-10}
-----------------

Zeb1 probe was used according to manufacturer's instructions.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"YAP drives cutaneous squamous cell carcinoma formation and progression\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Fiona Watt as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Eduardo Moreno (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this letter to draw your attention to significant concerns that you would need to address before this work could be considered for publication. Given the nature of the concerns, we request that you respond with proposed revisions and additional experimental work and an estimate of the time it would take to complete the essential changes. The editor and reviewers will then consider your proposal and issue a binding recommendation.

All reviewers thought this was a potentially interesting manuscript, but some experiments were a little preliminary at this stage. The conclusion that transgenic overexpression of constitutively nuclear and active YAP can drive spSCC formation was considered to be interesting. The authors also observed the formation of spindle cell carcinomas occurred at sites of wounding in their mice and this correlated with induction of Zeb1, although no direct mechanistic link was established. The authors attempted to correlate these observations in mice with studies of human cSCC and spindle cell carcinomas, although this requires further work (see below). Overall, the study, if improved, could provide evidence that nuclear YAP can drive spSCC formation on its own in K5-expressing cells at wound sites, and this may have potential relevance to human SCC.

Essential revisions:

1\) The human data presented appear to be only from a small number of examples in Figure 1 and Figure 1---figure supplement 1. The authors should perform their analyses on larger sample sets and perform statistical and quantitative analysis of staining intensity and percentages of cells within skin and lesions of their markers of interest to determine the generality of their claims.

2\) It is an important observation that spSCC can originate from K5-positive cells in the mouse. However, the LacZ lineage tracing is not clear enough in Figure 2C. The spindle SCC appears to be stained brown with little blue evident as presented. Clearer lineage tracing data (better LacZ staining) is required to substantiate this point.

3\) The majority of the manuscript relies on IHC without providing evidence of the specificity of the antibodies used under FFPE conditions? e.g. the proteins of interest should be stained with the antibodies used to illustrate specificity in FFPE +/- protein knockdown.

4\) The cooperation of YAP with Zeb1 for spSCC following wounding is interesting, but the data presented are correlative at this stage. The authors should extend these studies and provide evidence that Zeb1 is required for YAP effects in spSCC cells and/or provide more mechanistic links between YAP and ZEB1 (e.g. how does YAP influence ZEB1)?

5\) Is it possible for the authors to provide more information from their animal experiments indicating how many tumours per mouse were formed and over what time scale following induction of Cre, using frequency and/or Kaplan-Meier analyses?

6\) Can the authors provide evidence that the tumours specifically occurring at wounding sites are spSCCs (and not ulcerated tumours) -- they should have this data.

7\) Could the authors comment on why they think wounding contributes to spindle carcinomas. Is it just that the whole process of developing SCC tumours speeded up by a wound environment, e.g. via TGFbeta (which is known to cause spindle cell SCC tumours) or other inflammatory chemokines that cause a rapid EMT. Is YAP and Zeb1 needed for cSCC? This should be discussed.
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Author response

> Essential revisions:
>
> 1\) The human data presented appear to be only from a small number of examples in Figure 1 and Figure 1---figure supplement 1. The authors should perform their analyses on larger sample sets and perform statistical and quantitative analysis of staining intensity and percentages of cells within skin and lesions of their markers of interest to determine the generality of their claims.

As suggested, we have examined a panel of more than 20 human tumour samples and performed quantification of the YAP and ZEB1 expression to confirm the generality of our findings. The new data are in Figure 1---figure supplement 1 and Figure 5---figure supplement 1.

> 2\) It is an important observation that spSCC can originate from K5-positive cells in the mouse. However, the LacZ lineage tracing is not clear enough in Figure 2C. The spindle SCC appears to be stained brown with little blue evident as presented. Clearer lineage tracing data (better LacZ staining) is required to substantiate this point.

We apologise for any confusion caused here. In this experiment, the LacZ lineage is stained brown with anti-betaGal immunostaining, rather than blue (which is an eosin counterstain). Thus, the entire spSCC tumour is strongly betaGal positive, indicating that all tumour cells arise from the K5-positive lineage. The manuscript text and figure legend have been updated to clarify this point.

> 3\) The majority of the manuscript relies on IHC without providing evidence of the specificity of the antibodies used under FFPE conditions? e.g. the proteins of interest should be stained with the antibodies used to illustrate specificity in FFPE +/- protein knockdown.

The IHC antibodies used have all been previously validated, and we apologise for not explicitly stating this fact in the main text. For example, the YAP antibody used was validated by immunostaining YAP knockout mouse skin in our previous manuscript (Elbediwy et al., 2016). An example of confirmation by immunostaining a knockout mouse is shown in [Author response image 1](#respfig1){ref-type="fig"} (wild-type left, YAP/TAZ double knockout on the right).

![Validation of Rabbit anti-YAP antibody in knockout skin.](elife-33304-resp-fig1){#respfig1}

> 4\) The cooperation of YAP with Zeb1 for spSCC following wounding is interesting, but the data presented are correlative at this stage. The authors should extend these studies and provide evidence that Zeb1 is required for YAP effects in spSCC cells and/or provide more mechanistic links between YAP and ZEB1 (e.g. how does YAP influence ZEB1)?

To provide more mechanistic insight into the YAP-ZEB1 cooperation following wounding, we tested whether the induction of *Zeb1* mRNA by YAP in keratinocytes is mediated by TEAD-dependent transcription. This experiment entailed siRNA knockdown of TEAD1-4, which strongly reduced expression of ZEB1 after wounding. Furthermore, we have performed Chromatin Immunoprecipitation (ChIP) of TEAD1 binding to its cognate recognition site in the *Zeb1* promoter before and after scratch wounding of skin keratinocytes. This correlates with our finding that ZEB1 induction follows wounding and suggests that this is caused, at least in part, by the binding of YAP/TEAD1 to the *Zeb1* promoter. Notably, the *Zeb1* gene is well established as being crucial for EMT in cell culture models and in pancreatic cancer. To demonstrate that *Zeb1* is also required for YAP-driven EMT in mice is outside the scope of the manuscript, as this experiment would require us to obtain *Zeb1 floxed* mice, cross them to the K5-CreERT nlsYAP5SA mice and breed them to homozygosity for *Zeb1 floxed*, before obtaining sufficient numbers of offspring to perform quantitative analysis of the effects in histological samples of the resulting tumours (at least one year or longer).

> 5\) Is it possible for the authors to provide more information from their animal experiments indicating how many tumours per mouse were formed and over what time scale following induction of Cre, using frequency and/or Kaplan-Meier analyses?

Done. The data are now shown in Figure 2.

> 6\) Can the authors provide evidence that the tumours specifically occurring at wounding sites are spSCCs (and not ulcerated tumours) -- they should have this data.

Yes, we can confirm that we have always used histological analysis to define spSCCs and never rely on ulceration of the tumours as a proxy, as ulceration is also common in conventional SCC.

> 7\) Could the authors comment on why they think wounding contributes to spindle carcinomas. Is it just that the whole process of developing SCC tumours speeded up by a wound environment, e.g. via TGFbeta (which is known to cause spindle cell SCC tumours) or other inflammatory chemokines that cause a rapid EMT. Is YAP and Zeb1 needed for cSCC? This should be discussed.

Yes, we now include commentary on this point in the Results and Discussion section. It is indeed a fascinating future question how the wounding event synergises with YAP to induce ZEB1 expression and rapid EMT. We have proposed specific hypotheses, for future testing, regarding wound-induced signals that could cooperate with YAP to activate ZEB1 expression, based on our understanding of the ZEB1 promoter and additional information. As requested, we have also included discussion of the fact that ZEB1 is specifically involved in spSCC and cannot be involved in conventional cutaneous SCC, as it is not normally expressed in either normal skin or skin SCCs. YAP is, of course, necessary for cSCC as reported by the Piccolo lab and, very recently, the Blanpain lab (citation added).

[^1]: These authors contributed equally to this work.
